Back HIV/AIDS HIV/AIDS Topics HIV Treatment

Trial of CCR5-Deleted Stem Cell Gene Therapy for HIV Gets FDA Go-Ahead

The U.S. Food and Drug Administration (FDA) has given approval to proceed with a clinical trial of a gene therapy method that cuts the gene for the CCR5 coreceptor out of stem cells, making them resistant to HIV entry, the California Institute for Regenerative Medicine (CIRM) recently announced.

alt

Read more:

CROI 2015: Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells

Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle presented data on several experimental agents that may play a role in achieving a "functional cure" for HIV, or prolonged remission without disease progression. These include drugs that reactivate the latent HIV reservoir, interfere with expression of viral DNA, and help the immune system target HIV-infected cells.

alt

Read more:

CROI 2015: Early Antiretroviral Treatment Reduces, but Does Not Eliminate HIV Reservoir

Starting antiretroviral therapy (ART) very soon after infection may limit the size of the HIV reservoir and delay viral rebound after treatment interruption, according to several presentations at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. Other research showed that various biomarkers may predict who will experience HIV rebound after stopping ART.

alt

Read more:

CROI 2015: Does Emtricitabine Work Better than Lamivudine in Combination ART?

People with HIV who started an antiretroviral regimen containing emtricitabine (FTC; Emtriva) and NNRTIs were about half as likely to experience virological treatment failure as those who used the similar drug lamivudine (3TC; Epivir), according to an analysis of more than 6000 participants in the Dutch ATHENA cohort presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle. No significant differences between emtricitabine and lamivudine were seen with boosted protease inhibitor regimens.

alt

Read more:

CROI 2015: Cabotegravir and Rilpivirine Effective for HIV Maintenance Therapy at 96 Weeks

A combination of 2 once-daily oral antiretrovirals -- the next-generation integrase inhibitor cabotegravir (GSK1265744) and the approved NNRTI rilpivirine -- was as effective as an efavirenz-based regimen when used as maintenance therapy to keep viral load suppressed, according to a poster presented at the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more:

CROI 2015: Researchers Discuss HIV Cure Strategies

Researchers at the recent 2015 Conference on Retroviruses and Opportunistic Infections in Seattle discussed a variety of approaches to achieve a functional cure, or prolonged remission of HIV. Most experts expect that a combination of multiple approaches will be needed.

Early Antiretroviral Treatment Reduces, but Does Not Eliminate HIV Reservoir

Experimental Agents Reverse HIV Latency, Help Immune System Fight Infected Cells

We May Need to Combine Many Approaches to Achieve a Cure for HIV

3/20/15

alt

 

CROI 2015: We May Need to Combine Many Approaches to Achieve a Cure for HIV

It is unlikely that one single approach will achieve a cure for HIV infection, according to research presenting at a community cure workshop held the day before the recent 2015 Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle.

alt

Read more: